Nature

p28, A first in class peptide inhibitor of cop1 binding to p53

A 28 amino-acid (aa) cell-penetrating peptide (p28) derived from azurin, a redox protein secreted from the opportunistic pathogen Pseudomonas aeruginosa, produces a post-translational increase in p53 ...
ascopubs.org

A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors.

Phase I clinical trial of cancer vaccine with five novel epitope peptides for patients with metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I.
ascopubs.org

Mechanism of action of p28, a first-in-class, non-HDM2 mediated peptide inhibitor of p53 ubiquitination.

Silencing of SLC35F2 gene influences the biologic behavior of human lung cancer cell line H1299. The effect of blocking the prosurvival AKT/P13K/mTOR and mutant KRAS–signaling pathways on chemotherapy ...
BioWorld

NewCo News: CDG's p28 Shines in Phase I; ASCO Debut a 'Turning Point'

Amid the flood of data reported at last month's American Society of Clinical Oncology (ASCO) meeting, small biotech CDG Therapeutics Inc. emerged from a decade of stealth with the first clinical data ...